

API	Indication	R&D Validation batches	DMF
RESPIRATORY			
Abediterol	Asthma and COPD	early R&D	
Acclidinium bromide	COPD	R&D	
Arformoterol tartrate ^P polymorph A and D	COPD	√	√
Batefenterol	COPD	early R&D	
Formoterol fumarate	Asthma and COPD	√ ^{CoS}	√
Glycopyrronium bromide ^P	COPD	√	√
Indacaterol maleate ^P	Asthma and COPD	√	2019
Olodaterol	COPD	Q2 2018	
Revefenacin	COPD	R&D	
Salbutamol/Albuterol sulfate	Asthma and COPD	√	2018
Salmeterol xinafoate ^P	Asthma and COPD	√ ^{CoS}	√
Tiotropium Bromide (monohydrate/anhydrate/ amorphous)	COPD	√	
Umeclidinium bromide	COPD	√	
Vilanterol trifenate	Asthma and COPD	Q2 2018	
GENERICS			
Apixaban	Venous thromboembolism	√	2017
Aprepitant	Emesis	√	2017
Asenapine ^P	Schizophrenia and acute mania	√	√
Brexpiprazole	Schizophrenia and major depressive disorder	2018	
Brivaracetam	Antiepileptic	early R&D	
Carvedilol	Hypertension, angina, heart failure	√	√
Cinacalcet	Hyperparathyroidism / Hypercalcaemia	√	2018
Clevidipine	Hypertension	lab. samples	
Clomethiazole	Insomnia	√	√
Crisaborole	Atopic dermatitis and psoriasis	√	2019
Desloratadine	Allergy	√	√

CoS = Products with Certificate of Suitability

P = Patent applications/granted patents owned by NuPharm Group

Member of the  NuPharm Group

Products protected by valid patents are developed with no commercial purposes. These products are under development for uses related to the activities stated in the Art. 10.6 of the Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 and in the Art. 61.1(c) of the Spanish Patent Act, i.e. activities carried out to obtain a Marketing Authorization in Spain or out of Spain. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents"

API	Indication	R&D Validation batches	DMF
GENERICs			
Dronedarone	Atrial fibrillation & general arrhythmia	√	√
Eletriptan HBr	Migraine	√	√
Enalapril maleate	Hypertension	√	√
Fluconazol	Antifungal	√ ^{CoS}	√
Granisetron base	Emesis	√	√
Granisetron HCl	Emesis	√ ^{CoS}	√
Iloperidone	Schizophrenia and other psychotic disorders	√	
Imidafenacin	Urinary incontinence	√	2018
Imidapril	Hypertension	√	√
Loratadine	Allergy	√	√
Luliconazole	Antifungal	√	2019
Montelukast sodium	Asthma, allergic & seasonal rhinitis	√	√
Nitrendipine	Hypertension	√ ^{CoS}	√
Olanzapine	Schizophrenia, psychosis	√	√
Olanzapine pamoate (sterile)	Schizophrenia, psychosis	√	2019
Olmesartan medoxomil	Hypertension	√	
Ondansetron base ^P	Emesis	√	√
Ondansetron hydrochloride	Emesis	√ ^{CoS}	√
Prasugrel base ^P	Prophylaxis and therapy of thrombosis	√	√
Prasugrel hydrochloride	Prophylaxis and therapy of thrombosis	√	
Quetiapine hemifumarate	Schizophrenia, psychosis	√	√
Risperidone	Schizophrenia, psychosis	√ ^{CoS}	√
Rivaroxaban	Thrombosis. Stroke	√	2018
Rizatriptan benzoate	Migraine	√	√
Roflumilast	COPD with chronic bronchitis	√	
Telmisartan	Hypertension	√	√
Tetrabenazine	Parkinson disease	√	
(+) Tetrabenazine	Parkinson disease	√	
Tolvaptan	Hiponatremia	√	2018
Zolmitriptan	Migraine	√	√

CoS = Products with Certificate of Suitability

P = Patent applications/granted patents owned by NuPharm Group

Member of the  NuPharm Group

Products protected by valid patents are developed with no commercial purposes. These products are under development for uses related to the activities stated in the Art. 10.6 of the Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 and in the Art. 61.1(c) of the Spanish Patent Act, i.e. activities carried out to obtain a Marketing Authorization in Spain or out of Spain. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents"